Trial Profile
Intraoperative Imaging of Colon Cancer Using a Fluorescent Peptide (EMI-137) Against the c-Met Receptor
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs EMI-137 (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Diagnostic use
- 17 Jan 2020 This trial is completed (Global End Date: 29 Aug 2019), according to European Clinical Trials Database record.
- 12 Oct 2018 Planned End Date changed from 14 Sep 2018 to 14 Mar 2019.
- 12 Oct 2018 Planned primary completion date changed from 14 Aug 2018 to 14 Feb 2019.